Medtronic To Acquire Contego Medical For $380 Mln
Medtronic (MDT) agreed to acquire Contego Medical for $380 million, expanding its carotid and peripheral vascular products. The deal includes Contego's Neuroguard and Excipio devices. Medtronic expects completion in Q3 FY2024, with minimal EPS dilution in FY2027-2028. Shares rose 0.62% to $103.50 in overnight trading.
How this was made
The 30-second read
Why it matters
The acquisition is expected to be minimally dilutive to earnings and may provide incremental growth in the carotid and peripheral vascular segments.
Market read
First‑report M&A news with a $380 M deal size; stock reacted positively in overnight trade.
What to watch
Potential regulatory review and post‑acquisition integration costs are not detailed.
Background
Medtronic (MDT) disclosed a $380 million acquisition of privately held Contego Medical, adding the Neuroguard IEP Direct System and Excipio thrombectomy devices.
Ticker impact
Medtronic announced a $380 million acquisition of Contego Medical, adding new vascular products and expected to be minimally dilutive.
likely modest upside as investors price in the strategic expansion
First‑report M&A of significant size; market already nudged the stock up 0.62% in overnight trading.
Market effects
strengthens Medtronic's position in the vascular and neuro‑intervention market, potentially pressuring peers.
U.S. medical‑device sector may see slight uplift from the strategic acquisition.
Limited to Medtronic and its competitive set; no broad macro impact.
Counterpoint
Deal size is modest relative to Medtronic's scale; integration risk could weigh on the stock.
Key entities
- CompanyMedtronic Plc
US‑listed medical‑device maker acquiring Contego.
- CompanyContego Medical
Privately held developer of vascular devices.


